TMS Co., Ltd. (JP:4891)
:4891
Want to see JP:4891 full AI Analyst Report?
4891 Stock Chart & Stats
¥129.00
-¥1.00(-0.47%)
At close: 4:00 PM EST
¥129.00
-¥1.00(-0.47%)
Day’s Range― - ―
52-Week Range¥113.00 - ¥185.00
Previous CloseN/A
Volume100.70K
Average Volume (3M)256.91K
Market Cap
¥5.33B
Enterprise Value¥3.29B
Total Cash (Recent Filing)¥3.18B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Oct 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.99
Shares Outstanding45,565,765
10 Day Avg. Volume257,770
30 Day Avg. Volume256,913
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-25.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtA debt-free balance sheet is a durable risk-reducer for a cash-burning biotech. Absence of debt lowers fixed financing obligations, increases strategic flexibility to time fundraising or partnerships, and reduces bankruptcy risk while the company seeks commercial traction.
Prior Profitable Year (2022)The company achieved material revenue and positive cash flow in 2022, demonstrating the organization can generate commercial receipts or milestone income. That historical proof-of-concept reduces binary execution risk versus firms with never-positive operating results.
Lean Operating StructureA small headcount implies lower recurring payroll and overhead, which can extend runway absent revenue and make scarce capital go further. For an R&D-focused biotech, a lean team supports capital efficiency and focused project execution over the medium term.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flows are a central, durable risk: they deplete reserves, force repeated external funding, and raise dilution and execution pressure. Without durable cash generation or secured financing, program continuity and development timelines are at risk.
Multi-year Losses And Absent RevenueConsecutive deep losses and effectively absent recent revenue indicate the business model is not delivering recurring commercial income. This undermines sustainable margins and increases dependence on external financing or partnerships to fund R&D and commercial activities.
Eroding Equity BaseDeclining shareholders' equity erodes the company’s capital buffer and limits financial flexibility. Over time this weakens the ability to absorb setbacks, reduces optionality for non-dilutive financing, and raises the likelihood of dilutive capital raises or constrained investment in growth.
TMS Co., Ltd. News
4891 FAQ
What was TMS Co., Ltd.’s price range in the past 12 months?
TMS Co., Ltd. lowest stock price was ¥113.00 and its highest was ¥185.00 in the past 12 months.
What is TMS Co., Ltd.’s market cap?
TMS Co., Ltd.’s market cap is ¥5.33B.
When is TMS Co., Ltd.’s upcoming earnings report date?
TMS Co., Ltd.’s upcoming earnings report date is Oct 21, 2026 which is in 130 days.
How were TMS Co., Ltd.’s earnings last quarter?
TMS Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥4.49 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.49.
Is TMS Co., Ltd. overvalued?
According to Wall Street analysts TMS Co., Ltd.’s price is currently Overvalued.
Does TMS Co., Ltd. pay dividends?
TMS Co., Ltd. does not currently pay dividends.
What is TMS Co., Ltd.’s EPS estimate?
TMS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TMS Co., Ltd. have?
TMS Co., Ltd. has 45,565,765 shares outstanding.
What happened to TMS Co., Ltd.’s price movement after its last earnings report?
TMS Co., Ltd. reported an EPS of -¥4.49 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of TMS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4891
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TMS Co., Ltd.
Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.